Based on the results of our pooled analysis with individual data from almost 6000 patients, we found that six cycles of TC (TC6) provide similar efficacy compared to an anthracycline-containing regimen in most patients with HER2-negative early breast cancer and showed significantly lower incidence of overall grade 3/4 toxicities. Here, ERBB2 is linked to breast cancer.